論文・技術情報追加のお知らせ

1. Symptoms Associated With Gadolinium Exposure: Different Patterns and Rates Between Linear and Macrocyclic Gadolinium-Based Contrast Agents.

ガドリニウム造影剤の副作用解析

対象DB：FAERS

2. Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database.

便秘治療薬の副作用解析。リン酸化クロチドが最も安全

対象DB：FAERS

3. Hepatic adverse events associated with anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FAERS Database and analysis of drug-gene interaction network.

ALK阻害薬、肝障害のシグナルを確認

対象DB：FAERS

4. Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports.

FAERSで局所ミノキシジルの安全性を評価、過剰報告の解析

対象DB：FAERS

5. Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database.

レミマゾラムの副作用分析、特に高齢患者でアレルギー反応や呼吸・心停止に注意

対象DB：FAERS

6. A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system.

トラゾドンの副作用シグナルを分析し、新たな潜在的副作用を発見

対象DB：FAERS

7. Assessing the risk of acute kidney injury associated with a four-drug regimen for heart failure: a ten-year real-world pharmacovigilance analysis based on FAERS events.

HFrEF治療の四薬剤で、AKIや低血圧に要注意

対象DB：FAERS

8. Assessing the safety of midazolam: A comprehensive analysis of adverse events from FAERS.

ミダゾラムに関する重大な副作用

対象DB：FAERS

9. Analysis of Duloxetine-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System: Implications for Monitoring and Management.

デュロキセチンの副作用プロファイル

対象DB：FAERS

10. Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022.

JAK阻害薬の安全性プロファイル分析

対象DB：FAERS

11. Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.

プロテアソーム阻害薬による血栓性微小血管障害（TMA）のリスク

対象DB：FAERS

12. Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma.

クロザピンとリンパ腫の関連性

対象DB：FAERS

13. Otolaryngologic Side Effects of GLP-1 Receptor Agonists.

GLP-1受容体作動薬による耳鼻咽喉科の副作用解析

対象DB：FAERS

14. Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database.

リオシグアットの副作用解析

対象DB：FAERS

15. Postmarketing safety of [(177)Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system.

(177)Lu-PSMA-617の副作用解析

対象DB：FAERS

16. Comparative safety analysis of hedgehog inhibitor preparations: insights from the FAERS Database.

ビスモデギブとソニデギブの副作用比較

対象DB：FAERS

17. Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system.

アミオダロンの経路別副作用分析

対象DB：FAERS

18. Assessment the real-world safety of intravitreal dexamethasone implant (Ozurdex): novel insights from a comprehensive pharmacovigilance analysis utilizing the FAERS database.

眼科疾患治療におけるデキサメタゾンの安全性

対象DB：FAERS

19. Antibiotic-induced IgA vasculitis: insights from a real-world retrospective analysis and pharmacovigilance assessment.

抗生物質によるIgA血管炎のリスク

対象DB：FAERS

20. Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS.

タシメルテオンの使用で精神障害や不眠症などの新しいリスク

対象DB：FAERS

21. The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system.

COVID-19パンデミック中、ACEI使用で耳疾患や腎障害リスク増加

対象DB：FAERS

22. Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults.

ボリコナゾールは小児で精神障害、大人で肝胆道障害に関連

対象DB：FAERS

23. Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database.

ザヌブルチニブの副作用は予測通りで、新たなシグナルはなし

対象DB：FAERS

24. Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.

セットメラノチドの副作用には皮膚の色素沈着や注射部位反応

対象DB：FAERS

25. Ezetimibe-associated rhabdomyolysis: A comprehensive assessment of the USFDA adverse event reporting system using disproportionality analysis, case reviews and meta-analysis of randomized clinical trials.

エゼチミブ単独または併用で横紋筋融解症のリスク増加

対象DB：FAERS

26. Improving entity recognition using ensembles of deep learning and fine-tuned large language models: A case study on adverse event extraction from VAERS and social media.

LLMと深層学習モデルの組み合わせで副作用抽出性能向上

対象DB：FAERS,VAERS

27. Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.

薬剤性自己免疫性肝炎と関連の強い薬剤を特定

対象DB：FAERS

28. Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.

セマグルチドとNAIONの関連が示唆される

対象DB：FAERS

29. Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study.

デノスマブ、ロモズズマブ、レンバチニブが顎骨壊死に関連、特に高齢女性にリスク

対象DB：FAERS

30. Association of ocular adverse events with varenicline solution use: a population-based study.

バレニクリン点鼻薬は乾燥目の治療において特定の眼の副作用が報告されている

対象DB：FAERS

31. Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis.

JAK阻害薬はRA患者における眼の副作用リスクが異なる

対象DB：FAERS

32. Andexanet-induced Heparin Resistance in Cardiac Surgery - A Rapid Review of Case Reports and Series.

アンデキサネットはCPB中のヘパリン耐性を引き起こす

対象DB：FAERS

33. Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database.

HIF-PHIは心血管毒性、特に塞栓症、心不全、虚血性心疾患との関連が示唆される

対象DB：JADER

34. Global burden of vaccine-associated kidney injury using an international pharmacovigilance database.

COVID-19 mRNAワクチンは急性腎障害や糸球体腎炎、尿細管間質性腎炎と関連

対象DB：VigiBase

35. Second Opinion Referrals of Cancer Patients in Japan-A Nationwide Study.

日本のがん患者の1.6%がセカンドオピニオンを求め、治療開始に遅延

対象DB：DPC

36. Association Between Complementary Use of Daikenchuto (a Japanese Herbal Medicine) and Readmission in Older Patients With Heart Failure and Constipation.

大建中湯は便秘を伴う心不全患者の再入院率に影響なし

対象DB：DPC

37. Life course trajectories of maternal cardiovascular disease risk factors by obstetric history: a UK cohort study using electronic health records.

妊娠合併症歴は長期の心代謝リスクと関連

対象DB：CPRD

38. The impact of COVID vaccination on incidence of long COVID and healthcare resource utilisation in a primary care cohort in England, 2021-2022.

ワクチン接種は長期COVIDリスクを低減

対象DB：CPRD

39. The association between fibrotic diseases and treatment resistant hypertension in England.

治療抵抗性高血圧は線維化疾患と関連

対象DB：CPRD

40. Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England.

閉塞性肥大心筋症の負担はNYHA分類が高いほど増大

対象DB：CPRD

41. Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.

英国の小児喘息は重症度が高いほど医療負担増

対象DB：CPRD

42. Identifying children who develop severe chronic kidney disease using primary care records.

小児CKDの早期診断は難しく、症状の予測力は低い

対象DB：CPRD

43. Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs.

DOACとジゴキシン併用で死亡リスク増加

対象DB：CPRD

44. Enhancing Adverse Event Reporting With Clinical Language Models: Inpatient Falls.

BERTモデルが転倒検出に優れ、報告精度向上に寄与

対象DB：KAERS

45. [Infusion-related reactions with human polyclonal immunoglobulins: Analysis from the French National Pharmacovigilance Database].

免疫グロブリン投与で発熱など発生

対象DB：FPVD

46. Fractional CO(2) laser for the treatment of Peyronie's disease A pilot clinical trial.

CO?レーザーでPDの湾曲が改善し安全

対象DB：CVAR

47. Risk of Fracture Associated with Pregabalin or Mirogabalin Use: A Case-Case-Time-Control Study Based on Japanese Health Insurance Claims Data.

プレガバリンとミロガバリンは骨折リスク増

対象DB：DeSC

48. Differential coronary heart disease risk among antihypertensive and lipid-lowering medication users versus non-users: A real-world data analysis.

降圧薬使用者は非使用者よりCHDリスクが高く、生活習慣改善が重要

対象DB：DeSC